Synergistic Therapeutics announces it has obtained a US patent for its topical analgesic lotion, Dolore

Synergistic Therapeutics announces it has obtained a US patent for its topical analgesic lotion, Dolore

Tuesday, November 19, 2019

This is because studies have generic viagra cialis shown that bodily or psychological and emotion factors are at the risk of heart disease. Our answer is “Stem Alive.” Stem Alive is the only product on the market with a viagra cialis online ‘generic’ tag. He wishes to make the on line viagra women say wow in bed. It has the same dynamic solution and formula as the brand drugs are. generic viagra uk unica-web.com

DrugName : Dolore

 

Synergistic Therapeutics LLC has recently announced the issuance of a U.S. Patent for a Topical Analgesic Lotion that relieves pain. Synergistic Therapeutics LLC, a Florida-based company formed in 2015, specializes in manufacturing and formulating topical and sublingual pharmaceutical solutions.

Dolore is a topical pharmaceutical composition with unique properties and multiple components, including the addition of a perfusing agent, all combining to eliminate a wide variety of pain complications. Using a topical medication over an oral consumption is especially beneficial for those who use pain medications on a regular basis.

It provides deep penetration to get to the root of the problem area and remains focused on the affected location while limiting systemic side effects. With its patented prescription formula, Dolore has shown dramatic positive efficacy and scientific study results.

In addition to the analgesic lotion, Synergistic Therapeutics maintains and holds patents for other products, including Felicita, Cresere, and Minervo. Felicita is a sublingual ketamine lozenge to treat depression, including treatment-resistant depression (TRD).

[huge_it_slider id=”15″]
Cresere is a topical hair loss slowing and regrowth lotion. Minervo is a therapeutic neuropathic pain lotion. The company also is developing a female sexual dysfunction treatment.

Key PAtents:
Title Ctr PubDate
Appl.No Applicant Inventor Int.Class
TOPICAL ANALGESIS LOTON
 EP 13.06.2018
16833929 SYNERGISTIC THERAPEUTICS LLC SALCE ANTHONY H JR
A61K 45/06
Technologies are described for a formulation and production of a formulation. The methods may comprise depositing a non-steroidal anti-inflammatory drug (NSAID) compound into a chamber. The methods may comprise depositing a muscle relaxant into the chamber. The methods may comprise depositing a calcium channel blocker into the chamber. The methods may comprise depositing a general anesthetic into the chamber. The methods may comprise depositing a local anesthetic into the chamber. The methods may comprise milling and mixing the NSAID compound, the muscle relaxant, the calcium channel blocker, the general anesthetic, and the local anesthetic into a powder. The methods may comprise adding a solvent with the powder. The methods may comprise mixing the solvent with the powder to form a solution. The methods may comprise adding a base cream to the solution. The methods may comprise mixing the base cream and the solution to form the formulation.
TOPICAL ANALGESIC LOTION
 CA 09.02.2017
2994752 SYNERGISTIC THERAPEUTICS, LLC
A61K 45/06
Technologies are described for a formulation and production of a formulation. The methods may comprise depositing a non-steroidal anti-inflammatory drug (NSAID) compound into a chamber. The methods may comprise depositing a muscle relaxant into the chamber. The methods may comprise depositing a calcium channel blocker into the chamber. The methods may comprise depositing a general anesthetic into the chamber. The methods may comprise depositing a local anesthetic into the chamber. The methods may comprise milling and mixing the NSAID compound, the muscle relaxant, the calcium channel blocker, the general anesthetic, and the local anesthetic into a powder. The methods may comprise adding a solvent with the powder. The methods may comprise mixing the solvent with the powder to form a solution. The methods may comprise adding a base cream to the solution. The methods may comprise mixing the base cream and the solution to form the formulation.
THERAPEUTIC NEUROPATHIC PAIN LOTION
 CA 18.10.2018
3059435 SYNERGISTIC THERAPEUTICS, LLC
A61K 31/135
Technologies are described for a formulation and production of a formulation. The methods may comprise depositing a non-steroidal anti-inflammatory drug (NSAID) compound into a chamber. The methods may comprise depositing a N-methyl-D-aspartate (NMDA) receptor antagonist into the chamber. The methods may comprise respectively depositing a muscle relaxant, a local anesthetic into the chamber, depositing an anticonvulsant into the chamber, depositing an antidepressant into the chamber, and depositing a calcium channel blocking agent into the chamber. The methods may comprise milling the NSAID compound, the NMDA receptor antagonist, the muscle relaxant, the local anesthetic, the anticonvulsant, the antidepressant, and the calcium channel blocking agent into a powder. The methods may comprise adding a solvent with the powder and mixing the solvent with the powder to form a solution. The methods may comprise adding a base cream to the solution and mixing the base cream and the solution to form the formulation.
THERAPEUTIC NEUROPATHIC PAIN LOTION
 WO 18.10.2018
PCT/US2018/027272 SYNERGISTIC THERAPEUTICS. LLC SALCE, Anthony H.
A61K 31/135
Technologies are described for a formulation and production of a formulation. The methods may comprise depositing a non-steroidal anti-inflammatory drug (NSAID) compound into a chamber. The methods may comprise depositing a N-methyl-D-aspartate (NMDA) receptor antagonist into the chamber. The methods may comprise respectively depositing a muscle relaxant, a local anesthetic into the chamber, depositing an anticonvulsant into the chamber, depositing an antidepressant into the chamber, and depositing a calcium channel blocking agent into the chamber. The methods may comprise milling the NSAID compound, the NMDA receptor antagonist, the muscle relaxant, the local anesthetic, the anticonvulsant, the antidepressant, and the calcium channel blocking agent into a powder. The methods may comprise adding a solvent with the powder and mixing the solvent with the powder to form a solution. The methods may comprise adding a base cream to the solution and mixing the base cream and the solution to form the formulation.
Topical analgesic lotion
 US 09.02.2017
15229434 SYNERGISTIC THERAPEUTICS, LLC Anthony H. Salce, Jr.
A61K 31/195

Technologies are described for a formulation and production of a formulation. The methods may comprise depositing a non-steroidal anti-inflammatory drug (NSAID) compound into a chamber. The methods may comprise depositing a muscle relaxant into the chamber. The methods may comprise depositing a calcium channel blocker into the chamber. The methods may comprise depositing a general anesthetic into the chamber. The methods may comprise depositing a local anesthetic into the chamber. The methods may comprise milling and mixing the NSAID compound, the muscle relaxant, the calcium channel blocker, the general anesthetic, and the local anesthetic into a powder. The methods may comprise adding a solvent with the powder. The methods may comprise mixing the solvent with the powder to form a solution. The methods may comprise adding a base cream to the solution. The methods may comprise mixing the base cream and the solution to form the formulation.
Therapeutic neuropathic pain lotion
 US 18.10.2018
15951866 SYNERGISTIC THERAPEUTICS, LLC Anthony H. Salce, Jr.
A61K 31/485

Technologies are described for a formulation and production of a formulation. The methods may comprise depositing a non-steroidal anti-inflammatory drug (NSAID) compound into a chamber. The methods may comprise depositing a N-methyl-D-aspartate (NMDA) receptor antagonist into the chamber. The methods may comprise respectively depositing a muscle relaxant, a local anesthetic into the chamber, depositing an anticonvulsant into the chamber, depositing an antidepressant into the chamber, and depositing a calcium channel blocking agent into the chamber. The methods may comprise milling the NSAID compound, the NMDA receptor antagonist, the muscle relaxant, the local anesthetic, the anticonvulsant, the antidepressant, and the calcium channel blocking agent into a powder. The methods may comprise adding a solvent with the powder and mixing the solvent with the powder to form a solution. The methods may comprise adding a base cream to the solution and mixing the base cream and the solution to form the formulation.
TOPICAL ANALGESIS LOTON
 WO 09.02.2017
PCT/US2016/045740 SYNERGISTIC THERAPEUTICS, LLC SALCE, Anthony, H. Jr.
A61K 45/06
Technologies are described for a formulation and production of a formulation. The methods may comprise depositing a non-steroidal anti-inflammatory drug (NSAID) compound into a chamber. The methods may comprise depositing a muscle relaxant into the chamber. The methods may comprise depositing a calcium channel blocker into the chamber. The methods may comprise depositing a general anesthetic into the chamber. The methods may comprise depositing a local anesthetic into the chamber. The methods may comprise milling and mixing the NSAID compound, the muscle relaxant, the calcium channel blocker, the general anesthetic, and the local anesthetic into a powder. The methods may comprise adding a solvent with the powder. The methods may comprise mixing the solvent with the powder to form a solution. The methods may comprise adding a base cream to the solution. The methods may comprise mixing the base cream and the solution to form the formulation.
TOPICAL CORNEAL ANALGESIA USING NEUROTENSIN RECEPTOR AGONISTS AND SYNERGISTIC NEUROTENSIN COMBINATIONS WITHOUT DELAYING WOUND HEALING
 WO 18.09.2008
PCT/US2008/056721 SARENTIS THERAPEUTICS, INC. BARBUT, Denise
A01N 37/18
A method for administering an ocular analgesic is described. The method includes the steps of providing a topical analgesic that includes a neo-tryptophan-containing neurotensin analog and applying the topical analgesic to the ocular tissue in a dose of about 0.0005 to about 1.2 mg, alternatively about 0.0005 to about 1.0 mg, alternatively about 0.00075 to about 1.0 mg, alternatively about 0.001 mg to about 1.0 mg, alternatively about 0.001 mg to about 0.8 mg, alternatively about 0.001 mg to about 0.7 mg, alternatively about 0.001 mg to about 0.6 mg. Methods of administering a topical analgesic containing a neo-tryptophan-containing neurotensin analog are also described. The topical analgesic can be administered in a patch, gel, lotion, spray, or mist.
TOPICAL CORNEAL ANALGESIA USING NEUROTENSIN RECEPTOR AGONISTS AND SYNERGISTIC NEUROTENSIN COMBINATIONS WITHOUT DELAYING WOUND HEALING
 CA 18.09.2008
2680704 SARENTIS THERAPEUTICS, INC. BARBUT, DENISE
A61K 38/08
A method for administering an ocular analgesic is described. The method includes the steps of providing a topical analgesic that includes a neo-tryptophan-containing neurotensin analog and applying the topical analgesic to the ocular tissue in a dose of about 0.0005 to about 1.2 mg, alternatively about 0.0005 to about 1.0 mg, alternatively about 0.00075 to about 1.0 mg, alternatively about 0.001 mg to about 1.0 mg, alternatively about 0.001 mg to about 0.8 mg, alternatively about 0.001 mg to about 0.7 mg, alternatively about 0.001 mg to about 0.6 mg. Methods of administering a topical analgesic containing a neo-tryptophan-containing neurotensin analog are also described. The topical analgesic can be administered in a patch, gel, lotion, spray, or mist.
Topical corneal analgesia using neurotensin receptor agonists and synergistic neurotensin combinations without delaying wound healing
 AU 01.10.2009
2008225100 Mayo Foundation for Medical Education and Research
A01N 37/18
A method for administering an ocular analgesic is described. The method includes the steps of providing a topical analgesic that includes a neo-tryptophan-containing neurotensin analog and applying the topical analgesic to the ocular tissue in a dose of about 0.0005 to about 1.2 mg, alternatively about 0.0005 to about 1.0 mg, alternatively about 0.00075 to about 1.0 mg, alternatively about 0.001 mg to about 1.0 mg, alternatively about 0.001 mg to about 0.8 mg, alternatively about 0.001 mg to about 0.7 mg, alternatively about 0.001 mg to about 0.6 mg. Methods of administering a topical analgesic containing a neo-tryptophan-containing neurotensin analog are also described. The topical analgesic can be administered in a patch, gel, lotion, spray, or mist.
TOPICAL CORNEAL ANALGESIA USING NEUROTENSIN RECEPTOR AGONISTS AND SYNERGISTIC NEUROTENSIN COMBINATIONS WITHOUT DELAYING WOUND HEALING
 US 01.10.2015
14512250 SARENTIS THERAPEUTICS, INC. DENISE BARBUT
A61K 38/08

A method for administering an ocular analgesic is described. The method includes the steps of providing a topical analgesic that includes a neo-tryptophan-containing neurotensin analog and applying the topical analgesic to the ocular tissue in a dose of about 0.0001 to about 5 mg, alternatively about 0.0001 to about 3 mg, alternatively about 0.0005 to about 1.2 mg, alternatively about 0.0005 to about 1.0 mg, alternatively about 0.00075 to about 1.0 mg, alternatively about 0.001 mg to about 1.0 mg, alternatively about 0.001 mg to about 0.8 mg, alternatively about 0.001 mg to about 0.7 mg, alternatively about 0.001 mg to about 0.6 mg. Methods of administering a topical analgesic containing a neo-tryptophan-containing neurotensin analog are also described. The topical analgesic can be administered in a patch, gel, lotion, spray, or mist.
Key Facts
    •  News CategoryIntellectual Property
      Other Product News
      Product Development
    •  CompanySynergistic Therapeutics LLC
    •  CountryNorth America > United States of America

Leave a Reply

Your email address will not be published. Required fields are marked *

89 − 80 =